Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2024.
All research outputs
#2,051,627
of 34,307,719 outputs
Outputs from Journal of Clinical Oncology
#5,812
of 32,278 outputs
Outputs of similar age
#7,759
of 161,124 outputs
Outputs of similar age from Journal of Clinical Oncology
#44
of 416 outputs
Altmetric has tracked 34,307,719 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,278 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 161,124 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 416 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.
